SEC Company Response from ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Jun 23, 2006

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: June 23, 2006 · CIK: 0000727510 · Accession: 0001125282-06-003674

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

June 23, 2006

Author

Craig A. Tooman

Form

CORRESP

Company

ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)

Letter

Re: Enzon Pharmaceuticals, Inc.

Prepared and filed by St Ives Financial

ENZON PHARMACEUTICALS, INC.

685 Route 202/206 Bridgewater, NJ 08807

June 23, 2006

VIA EDGAR: Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Celeste M. Murphy, Esq.

Schedule TO filed June 6, 2006 (File No. 005-35587 )

Ladies and Gentlemen:

Enzon Pharmaceuticals, Inc. (the “Company”) hereby acknowledges the following:

1. The Company is responsible for the adequacy and accuracy of the disclosure in the filings;

2. Staff comments or changes to disclosure in response to Staff comments in the filings reviewed by the Staff do not foreclose the Commission from any action with respect to the filing; and

3. The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
ENZON PHARMACEUTICALS, INC.

Show Raw Text

CORRESP
1
filename1.htm

Prepared and filed by St Ives Financial

ENZON PHARMACEUTICALS, INC.

685 Route 202/206
Bridgewater, NJ 08807

June 23, 2006

VIA EDGAR:
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Celeste M. Murphy, Esq.

Re:
Enzon Pharmaceuticals, Inc.

  Schedule TO filed June 6, 2006 (File No. 005-35587 )

Ladies and Gentlemen:

Enzon Pharmaceuticals, Inc. (the “Company”) hereby acknowledges the following:

1.
The Company is responsible for the adequacy and
    accuracy of the disclosure in the filings;

2.
Staff comments or changes to disclosure in response to Staff comments in the filings reviewed by the Staff do not foreclose the Commission from any action with respect to the filing; and

3.
The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,

ENZON PHARMACEUTICALS, INC.

By: /s/ Craig A. Tooman

       Name:   Craig A. Tooman

Title:      Executive Vice President, Finance

                   and Chief Financial Officer

SecProbe.io